Study | study type
|
Pathology | T1 | T0 | Patients | sample sizes | ROB | Results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
versus Standard of Care (SoC) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
pembrolizumab alone | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
KEYNOTE-042 (PDL1>50%), 2019 NCT02220894 | RCT | mNSCLC - L1 - PDL1 positive | pembrolizumab | platinium based chemotherapy | previously untreated, locally advanced or metastatic non-small-cell lung cancer with a PD-L1 TPS of 50% or greater | 299 / 300 | some concern | conclusif |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
KEYNOTE-042 (PDL1>20%), 2019 NCT02220894 | RCT | mNSCLC - L1 - PDL1 positive | pembrolizumab | platinium based chemotherapy | previously untreated, locally advanced or metastatic non-small-cell lung cancer with a PD-L1 TPS of 20% or greater | 413 / 405 | some concern | conclusif |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
KEYNOTE-042 (PDL1>1%), 2019 NCT02220894 | RCT | mNSCLC - L1 - PDL1 positive | pembrolizumab | platinium based chemotherapy | previously untreated, locally advanced or metastatic non-small-cell lung cancer with a PD-L1 TPS of 1% or greater | 637 / 637 | some concern | conclusif |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
KEYNOTE-024 (PDL1>50%), 2016 NCT02142738 | RCT | mNSCLC - L1 - PDL1 positive | Pembrolizumab | ICC platinum-based chemotherapies regimens | patients who had previously untreated advanced stage IV NSCLC with PD-L1 expression on at least 50% of tumor cells | 154 / 151 | some concern | conclusif |
|